Zevra Non Currrent Assets Other from 2010 to 2024
| ZVRA Stock | 9.51 0.00 0.00% |
Non Currrent Assets Other | First Reported 2013-12-31 | Previous Quarter 11.1 M | Current Value 9.3 M | Quarterly Volatility 3 M |
Check Zevra Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zevra Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Selling General Administrative of 26 M or Other Operating Expenses of 80.9 M, as well as many indicators such as Price To Sales Ratio of 5.9, Dividend Yield of 0.0 or PTB Ratio of 3.94. Zevra financial statements analysis is a perfect complement when working with Zevra Therapeutics Valuation or Volatility modules.
Zevra | Non Currrent Assets Other |
Latest Zevra Therapeutics' Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of Zevra Therapeutics over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Zevra Therapeutics' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zevra Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
Zevra Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | 1,799,904 | |
| Coefficient Of Variation | 194.72 | |
| Mean Deviation | 2,406,801 | |
| Median | 438,000 | |
| Standard Deviation | 3,504,731 | |
| Sample Variance | 12.3T | |
| Range | 10.8M | |
| R-Value | 0.61 | |
| Mean Square Error | 8.3T | |
| R-Squared | 0.38 | |
| Significance | 0.02 | |
| Slope | 480,542 | |
| Total Sum of Squares | 172T |
Zevra Non Currrent Assets Other History
About Zevra Therapeutics Financial Statements
Zevra Therapeutics stakeholders use historical fundamental indicators, such as Zevra Therapeutics' Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Zevra Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Zevra Therapeutics' assets and liabilities are reflected in the revenues and expenses on Zevra Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Zevra Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | 9.9 M | 10.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zevra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zevra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zevra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zevra Therapeutics Stock:Check out the analysis of Zevra Therapeutics Correlation against competitors. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.575 | Quarterly Revenue Growth 0.276 | Return On Assets (0.33) | Return On Equity (1.31) |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.